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ABSTRACT
Introduction: A comprehensive and up-to-date
network meta-analysis (NMA) helps to
determine the comparative efficacies of
nucleos(t)ide analogs (NAs) in patients with
chronic hepatitis B (CHB). The aim of this NMA
was to assess the efficacy of telbivudine versus
adefovir, entecavir, lamivudine, and tenofovir
in nucleos(t)ide-naı¨ve hepatitis B e antigen
(HBeAg)-positive patients with CHB.
Methods: A systematic review was conducted to
search Medline, Medline-In Process, EMBASE,
and the Cochrane Central Register of
Controlled Trials databases for publications of
randomized controlled trials (RCTs). NMA was
performed to compare the efficacy outcomes of
telbivudine versus other approved NAs at 1- and
2-year time points.
Results: A total of 75 RCTs were included in the
systematic review. At the 1-year time point,
telbivudine was associated with significantly
higher rates of: (1) HBeAg seroconversion than
adefovir [odds ratio (OR) 1.99 (95% credible
interval (CrI): 1.05, 3.45)], entecavir [OR 2.00
(95% CrI: 1.44, 2.82)] and lamivudine [OR 1.49
(95% CrI: 1.10, 2.03)]; (2) HBeAg loss than
entecavir [OR 1.85 (95% CrI: 1.28, 2.76)] and
lamivudine [OR 1.62 (95% CrI: 1.20, 2.24)]; (3)
alanine aminotransferase (ALT) normalization
than lamivudine [OR 1.50 (95% CrI: 1.05,
2.21)]; and (4) hepatitis B virus (HBV) DNA
suppression than adefovir [OR 2.77 (95% CrI:
1.28, 5.45)] and lamivudine [OR 2.97 (95% CrI:
1.99, 4.53)]. At the 2-year time point, the
relative efficacy outcomes were not statistically
significant.
Conclusion: At 1 year, telbivudine was superior
to adefovir, entecavir and lamivudine in HBeAg
seroconversion, and to entecavir and
lamivudine in HBeAg loss. Telbivudine was
also superior to lamivudine in ALT
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Hepatitis B virus (HBV) infection is a major
global public health problem. It is estimated that
240 million people are chronically infected with
HBV worldwide and approximately
780000 deaths each year are attributed to
hepatitis B [1]. Chronic hepatitis B (CHB) can
cause severe liver inflammation and fibrosis,
ultimately resulting in more serious
complications such as cirrhosis, hepatic
decompensation and hepatocellular carcinoma
(HCC) [2]. In patients with CHB, the presence of
hepatitis B e antigen (HBeAg) indicates active
HBV replication and more severe infection.
Therefore, it may be useful to monitor HBeAg
levels in patients to determine treatment
response, as HBeAg seroconversion in
HBeAg-positive patients with sustained
undetectable HBV DNA may be considered as a
potential end point in the treatment of CHB [3].
Currently approved therapies for CHB
include two immune-based interferons
[interferon-a (IFN-a) and pegylated IFN a
(PEG-IFN a-2a or a-2b)] and five antiviral
nucleos(t)ide analogs (NAs), namely adefovir,
entecavir, lamivudine, telbivudine, and
tenofovir. These antivirals do not completely
eradicate HBV, and hence the efficacy of these
therapies is still unsatisfactory [2, 4]. At present,
NAs are most commonly used in
HBeAg-positive patients with CHB. HBeAg
seroconversion in patients with CHB is
associated with favorable long-term outcomes,
such as disease remission, lower incidence of
cirrhosis and HCC, and higher survival rates [3,
5, 6]. A number of systematic literature reviews
(SLRs) and meta-analyses have been published
on the efficacy of NAs for the treatment of CHB
[4, 7–10]. Although these meta-analyses
evaluated the efficacy of NAs, their scope was
limited primarily to direct comparisons of NAs
without considering indirect evidence using a
common comparator between two NAs, which
were not compared against each other in a
randomized controlled trial (RCT). There is only
one published meta-analysis which used a
mixed-treatment comparison of NAs [8], but
that study evaluated only 1-year efficacy
outcomes. It is necessary to compare the
available NAs through direct and indirect
comparisons beyond the 1-year time period to
have a more comprehensive overview of the
efficacy of current treatment options in CHB.
This can help physicians with selecting the
most appropriate NA treatment options based
on comparative efficacies. A network
meta-analysis (NMA) helps to synthesize and
analyze data by comparing multiple treatments
both directly and indirectly [11, 12]. To address
this need, we have performed SLR and NMA to
compare the efficacy of the approved NAs. The
aim of this meta-analysis was to assess the
efficacy of telbivudine compared to adefovir,




This SLR followed standard systematic review
methodology endorsed by the Cochrane
Collaboration [13] and the National Institute
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for Health and Care Excellence (NICE) in the UK
[14]. The SLR was conducted and reported in
accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [15]. This article is based
on previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Inclusion and Exclusion Criteria
All RCTs with HBeAg-positive,
nucleos(t)ide-naı¨ve patients with CHB were
identified. RCTs reporting both HBeAg-positive
and -negative patients were considered if
subgroup data for HBeAg-positive patients
were reported. Only those RCTs with
interventions or comparators (adefovir,
entecavir, lamivudine, telbivudine, tenofovir,
and placebo), with reported outcomes on
HBeAg seroconversion, HBeAg loss, HBV DNA
levels, alanine aminotransferase (ALT)
normalization, and hepatitis B surface antigen
(HBsAg) loss and seroconversion, were eligible
for inclusion. Exclusion criteria comprised
animal and in vitro studies; studies of patients
who were co-infected with hepatitis C, hepatitis
D, or human immunodeficiency viruses; studies
of patients with decompensated liver disease;
studies of HBeAg-negative patients; studies
which did not report interventions,
comparators, or the outcomes of interest; and
studies which were published in languages
other than English or Chinese. Review articles,
editorials, case reports, case series, economic
evaluations, abstracts, and poster presentations
were also excluded.
Search Strategy
A comprehensive literature search of Medline,
Medline-In Process, EMBASE, and the Cochrane
Central Register of Controlled Trials databases
was performed for relevant published studies
within the period from January 2004 to
February 2015. The search strategy was based
on the combination of medical subject
headings (MeSH) and key words including
‘‘adefovir’’, ‘‘entecavir’’, ‘‘lamivudine’’,
‘‘telbivudine’’, ‘‘tenofovir’’, ‘‘chronic hepatitis
B’’, ‘‘hepatitis B’’, ‘‘randomized controlled
trial’’, ‘‘random allocation’’, ‘‘clinical trial’’,
‘‘double-blind method’’, and ‘‘single-blind
method’’. The majority of relevant published
studies were in English and Chinese, and thus
both English and Chinese publications were
included in the literature search.
First-Level Screening of Citations
All the studies retrieved from the literature
search were screened based on the title and
abstract supplied with each citation. The
inclusion/exclusion criteria were uniformly
applied across all the studies. Two
independent reviewers for English and two for
Chinese publications screened the retrieved
abstracts, and any discrepancies between
reviewers were reconciled by a third
independent reviewer. Studies that did not
meet the eligibility criteria were excluded, and
reasons for exclusion were documented.
Full-text copies of all references that met the
inclusion criteria were then downloaded.
Second-Level Screening of Citations
The inclusion/exclusion criteria were uniformly
applied across all the full-text publications. The
same two reviewers for English and two for
Chinese publications screened all the
manuscripts, and any discrepancies between
reviewers were reconciled by a third
independent reviewer. Studies that did not
Adv Ther (2016) 33:519–531 521
meet the eligibility criteria were excluded, and
reasons for exclusion were documented. Studies
that met the inclusion criteria were subjected to
data extraction.
Data Extraction
The same reviewers extracted data
independently in a data extraction template,
with any discrepancies resolved by a third
independent reviewer. Data were extracted
based on different information from a study,
such as objectives, methods, inclusion and
exclusion criteria, baseline demographic and
clinical characteristics, interventions, efficacy
outcomes, and conclusion. Studies with
multiple publications were linked to one
another and extracted as a single study. The
full texts of the relevant articles were examined
to determine the relevance of data on study
objectives, design, inclusion/exclusion criteria,
patients, interventions, and efficacy outcomes.
The RCTs that met the inclusion criteria for the
review were critically appraised for quality
based on the recommendations by NICE [14].
Assessments of End Points
The primary end point of the analysis was
HBeAg seroconversion in patients with CHB.
HBeAg seroconversion was defined as HBeAg
loss and the appearance of anti-HBe antibodies.
Secondary end points included rates of HBeAg
loss, normalization of ALT, undetectable HBV
DNA levels, and HBsAg loss and seroconversion.
HBV DNA levels less than 1000 copies/mL (HBV
DNA \200, 300, 400, 500 copies/mL, etc.)
reported in studies were pooled together and
analyzed for the undetectable HBV DNA end
point. The study end points were analyzed at
1-year (48–52 weeks) and 2-year (96–104 weeks)
time points.
Statistical Analysis
The meta-analysis was performed employing
statistical methods that combine data from
various studies to obtain a coherent picture of
treatment outcomes and compare various
treatment options. The statistical models
related the underlying outcome to the effect of
treatments and any other factors (covariates).
The models for conducting NMA were taken
from the Report of the ISPOR Task Force on
Indirect Treatment Comparisons Good
Research Practices Part 2 and NICE TSD2 [16,
17]. For this analysis, Bayesian models were
used. To assess the heterogeneity with respect to
study location, age, and baseline HBV DNA
levels, exploratory analyses and random effects
Bayesian models with study level covariates
were used.
The statistical software R (version C3.0.2, R
Foundation for Statistical Computing, Vienna,
Austria) was used for data pre-processing and
statistical analysis. The integrated GUI for R,
Rstudio (version C0.97.551), was used to run all
the R scripts. The package R2WinBUGS was
used to retrieve WinBUGS 1.4 from R in order to
run the Bayesian Markov Chain Monte Carlo
algorithm. The results were reported in terms of




The results of the literature search are
summarized in Fig. 1. The search yielded 5499
publications. Of these, 1719 studies were
duplicates due to the overlap of records across
the databases. All 3780 studies went through
first-level screening (title/abstract screening).
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Following this, 432 publications were found to
be eligible. These were subjected to second-level
screening (full-text screening) and there were 86
publications remaining. The number of
publications excluded at each level of
screening and the corresponding reasons for
exclusion are presented in Fig. 1. A total of 24
Chinese publications were additionally
identified through bibliographic search (three
of these were duplicate Chinese articles),
resulting in a total of 107 publications. As
some publications were linked to one another,
the final list of publications included 75 studies
(37 English publications and 38 Chinese
publications).
Study Characteristics
Of the 75 included studies, 29 (39%) English
and 32 (43%) Chinese language studies were
active controlled. Only nine (12%) studies in
total were placebo controlled. Of the remaining
five studies, one compared lamivudine with
untreated controls and four were dose-ranging
studies. Of the 38 Chinese language studies, 29
(76%) were single center, whereas of the 37
English language studies, 26 (70%) were
multi-center. Almost all of the Chinese
language studies were phase IV trials and 14
(38%) of the English language studies were
phase III, with only four studies reported to be
Fig. 1 Flow diagram of the literature search
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phase II. More than half of the included studies
(52%) had 1-year duration in the randomized
phase.
In the included RCTs, lamivudine was the
most commonly assessed comparator
accounting for 24 studies. This was followed
by placebo, which was the comparator in 12 of
the included studies. NAs were assessed as
monotherapy in 58 of the included studies.
Overall, 19% of the included studies may be at
risk of bias: of these, 15% due to blinding
methodology and 4% due to statistical analysis.
When compared to English language studies, a
larger number of Chinese language studies did
not report the method of randomization,
allocation concealment, blinding, or statistical
analysis.
Randomization and allocation concealment
were reported to be adequate in 24% of the
included studies. Apart from blinding, more
than 50% of the included studies reported a low
risk of bias in terms of baseline characteristics,
patient withdrawals, selective outcome
reporting, and statistical analysis. About 15%
of the included English language studies were
considered to be at high risk of bias because of
their open-label design.
All the studies were conducted in
HBeAg-positive CHB patients. The details of
the demographic and disease characteristics of
study participants at baseline are listed in
Table S1 in the online supplementary
material. The sample size of the included
studies ranged from 14 to 921 [18, 19]. The
median age of the patients ranged from 24 to
44 years [10, 20]. The majority of studies
recruited primarily male patients; 37% of
these studies reported a male population
greater than 70%. The studies reported ALT
levels above 100 IU/L. Of 11 studies which
reported information on HBV genotypes, more
than 50% of the recruited patients had
genotype C as the major viral genotype,
indicating that the majority of the study
population represented is of Southeast Asian
descent [21]. The proportion of patients with
genotype B ranged from 8% to 41% among the
included studies which reported information
on HBV genotype [22, 23]. Table S2 in the
online supplementary material shows the total
numbers of patients in each treatment regimen
and the corresponding numbers of patients
with reported HBeAg seroconversion, HBeAg
loss, ALT normalization, and undetectable HBV
DNA.
HBeAg Seroconversion
Figure 2 shows the full network diagram for
evidence of treatment regimens with HBeAg
seroconversion outcomes at the 1-year time
point. A total of 40 studies reported HBeAg
seroconversion results. The relative efficacy of
NAs at the 1-year time point demonstrated
that telbivudine was superior to adefovir,
entecavir, and lamivudine (Fig. 3a). The
relative efficacy outcomes of telbivudine
versus other NAs at the 2-year time point
were not statistically significant. There were a
relatively small number of studies (14 studies)
which reported outcomes at the 2-year time
point.
HBeAg Loss
Thirty studies reported HBeAg loss results. The
NMA on relative efficacy at the 1-year time
point showed that telbivudine was superior to
entecavir and lamivudine for HBeAg loss in
patients with CHB (Fig. 3b). The relative efficacy
of NAs at the 2-year time point yielded no
statistically significant results.
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ALT Normalization
Thirty-two studies reported ALT normalization
results. The relative efficacy of NAs at the 1-year
time point is presented in Fig. 3c. The NMA
demonstrated that telbivudine was superior to
lamivudine in ALT normalization.
Undetectable HBV DNA
There were 34 studies that reported rates of
undetectable HBV DNA at 1 year of treatment.
The relative efficacy of NAs at the 1-year time
point (Fig. 3d) demonstrated that telbivudine
was superior to adefovir and lamivudine in
suppressing HBV DNA levels. Tenofovir was
superior to telbivudine in suppressing HBV
DNA levels.
Analysis of Heterogeneity
None of the factors including study location,
age, and baseline HBV DNA was found to affect
the results.
DISCUSSION
This comprehensive and up-to-date NMA
analyzed both direct and indirect evidence for
the comparative efficacies of NAs. To ensure as
comprehensive an approach as possible, we
incorporated both English and Chinese
Fig. 2 HBeAg seroconversion at 1 year—network diagram.
The numbers 1, 2, 3, etc. denote individual treatment
regimens with corresponding full names given on the right
side panel. This network diagram provides a summary of
direct and indirect evidence from trials in a graphical
manner. Each treatment is represented by a node, and a
serial number is provided for each node representing the
treatment regimen on the right side panel. The line
connecting two nodes represents the direct evidence
comparing the treatments. The numbers between the lines
represent the number of studies available for that particular
treatment comparison. The dark nodes indicate approved
monotherapy regimens, whereas light ones indicate other
therapeutic regimens from which indirect evidence is
obtained
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publications. We included indirect evidence
from combination therapies (as shown in
Fig. 2). As NMA provides pooled efficacy
estimates, the small sample size of some
studies did not affect the overall results.
The 1-year results from this NMA revealed
significant differences in HBeAg seroconversion
when comparing telbivudine and most of the
approved oral NAs. Telbivudine demonstrated
superior efficacy over adefovir, entecavir and
lamivudine in HBeAg seroconversion. The
clinical importance of HBeAg seroconversion
was reported in treatment guidelines. It is
considered as a potential treatment end point
in HBeAg-positive patients with
undetectable HBV DNA and persistently
normal ALT levels [3, 24]. HBeAg
seroconversion is associated with favorable
long-term outcomes, including reduced risk of
cirrhosis or HCC [3]. A long-term study in
patients with CHB showed that during a
median follow-up of approximately nine years
after spontaneous HBeAg seroconversion, the
majority (67%) of patients had sustained
remission [5]. Another study reported that the
rate of fibrosis progression was lower in patients
Fig. 3 Relative efﬁcacy at 1 year (odds ratio, credible interval): a HBeAg seroconversion, b HBeAg loss, c ALT
normalization, d undetectable HBV DNA
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with sustained disease remission (HBeAg
seroconversion and HBV DNA\104 copies/mL
at follow-up) as compared to patients who
remained HBeAg positive [25]. These reports
indicate that HBeAg seroconversion is an
important end point in the treatment of
patients with CHB.
The present analysis also demonstrated that
telbivudine was superior to entecavir and
lamivudine for inducing HBeAg loss, and to
lamivudine in ALT normalization. With regard
to reducing HBV DNA levels, telbivudine
demonstrated superior efficacy as compared to
adefovir and lamivudine, and similar efficacy to
entecavir. Outcomes at 1 year showed that
tenofovir was superior to telbivudine in
suppressing HBV DNA levels. However, there
were only two studies with tenofovir which
reported undetectable HBV DNA at the 1-year
time point. Data from an earlier meta-analysis
Fig. 3 continued
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showed that compared to other NAs, tenofovir
had the highest probability of achieving HBeAg
seroconversion after 1 year of treatment.
Tenofovir also showed significantly higher
HBV DNA reduction than the other NAs.
Entecavir was significantly superior to adefovir
and lamivudine, whereas telbivudine showed
superior efficacy than lamivudine [8]. However,
this meta-analysis by Wiens et al. has two major
limitations that were acknowledged by the
authors. First, a random-effect meta-analysis
software (ADDIS) was used, unlike the current
analysis that was performed using WinBUGS
1.4, a widely accepted software for conducting
Bayesian NMA. Second, the previously
published analysis included data from only
nine RCTs of 48–52 weeks duration. Hence,
results from this published analysis cannot be
extrapolated or generalized to real-life
situations.
Results from a prospective study showed that
treatment intensification (Roadmap approach)
with adefovir add-on therapy in patients with
suboptimal virologic response (HBV DNA
C300 copies/mL) after 24 weeks of telbivudine
treatment significantly improved efficacy
outcomes at 2 years. This shows that
adjustment of treatment strategy may be
useful for patients with suboptimal virologic
response to telbivudine treatment [23]. An
earlier study with Roadmap approach in
HBeAg-positive, nucleoside-naı¨ve patients with
CHB appeared to be an effective treatment
approach. Telbivudine with conditional
tenofovir intensification resulted in high rates
of undetectable HBV DNA, ALT normalization,
HBeAg/HBsAg clearance, and HBeAg
seroconversion. There was neither virologic
breakthrough nor resistance observed over
52 weeks of treatment [26]. Therefore,
telbivudine and tenofovir add-on therapy,
based on Roadmap approach, may be a useful
strategy to optimize antiviral treatment
outcomes in patients with suboptimal
virologic response.
The superiority of telbivudine over entecavir
with regard to HBeAg loss and HBeAg
seroconversion in this 1-year NMA was in
accordance with a previously published
meta-analysis that directly compared
telbivudine versus entecavir in treatment-naı¨ve
HBeAg-positive patients with CHB [10]. The
published direct meta-analysis concluded that
in nucleos(t)ide-naı¨ve Asian patients with CHB,
assessed at 12, 24, and 48 weeks after starting
the treatment, telbivudine was as effective as
entecavir in HBV DNA suppression, but had
higher rates of HBeAg loss and seroconversion
as compared to entecavir [10]. In the long-term
analysis at the 2-year time point, the relative
efficacies of telbivudine versus other NAs with
regard to HBeAg loss and HBeAg seroconversion
were not statistically significant. The analysis
was not conducted for other outcomes due to
the limited number of studies reporting data at
2 years. Earlier, 2-year results from the GLOBE
study (ClinicalTrials.gov identifier:
NCT00057265) showed that a subgroup of
HBeAg-positive patients with baseline HBV
DNA\9 log10 copies/mL, ALT level C29 upper
limit of normal, and undetectable HBV DNA at
week 24 achieved high rates of
undetectable HBV DNA (89%) and HBeAg
seroconversion (52%) with low rate of
telbivudine resistance (1.8%) at 2 years.
Therefore, the baseline characteristics of
patients with CHB and undetectable serum
HBV DNA at treatment week 24 (early
virologic response) may be considered as the
strongest predictors of long-term outcomes of
telbivudine treatment [27].
Several studies have shown that high HBV
DNA levels, high ALT levels, and
HBeAg-positivity are independent risk factors
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for the development of HCC and cirrhosis [28,
29]. Thus, effective antiviral therapy and
induction of HBeAg seroconversion may
lower the risk of developing HCC. The
possible mode of action for the
telbivudine-mediated high rate of HBeAg
seroconversion is through direct inhibition
of viral replication and stimulation of the host
immune response [30]. This suggests that
telbivudine provides potential benefits for
patients with HBeAg-positive CHB. It is
important to note that newer-generation oral
NAs need to be developed with the objective
of inducing higher rates of HBeAg loss and
seroconversion that are sustained over a long
period of time after the end of treatment. This
can provide the possibility of a finite therapy
for HBeAg-positive patients with CHB [6].
There are some limitations to this analysis. It
primarily evaluated HBeAg seroconversion and
other efficacy data. However, viral resistance
and adverse events due to NA treatment were
not assessed, although these are key factors
when selecting a particular therapy for CHB. An
evaluation of the cost-effectiveness of NAs was
not part of this NMA. The analysis mainly
reported results from RCTs with 1-year of
treatment. A limited number of studies
reported outcomes at the 2-year time point;
therefore, a more robust comparison was not
feasible. Hence, the NMA results are not reliable
at the 2-year time point due to the small
number of studies. Furthermore, the long-term
(C5 years) efficacies of NAs and the potential
benefits in the reduction of liver-related
complications were not determined. A
previous review on the use of NAs in
HBeAg-positive CHB patients reported that
rates of HBeAg loss increased up to 50% and
anti-HBe seroconversion up to 37% at year 6 of
treatment [31]. Given the chronic nature of the
disease, cohort studies to evaluate the long-term
outcomes after treatment with different NAs
would be important.
CONCLUSIONS
This SLR and NMA demonstrated that in
nucleos(t)ide-naı¨ve HBeAg-positive patients
with CHB, telbivudine was superior to
adefovir, entecavir, and lamivudine in HBeAg
seroconversion, and to entecavir and
lamivudine in HBeAg loss at 1 year of
treatment. Telbivudine also showed a superior
response as compared to lamivudine in ALT
normalization and to adefovir and lamivudine
in suppressing HBV DNA levels.
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